MPR YIR SpA 2018

Ixekizumab Tops Placebo in Axial Spondyloarthritis

The researchers found that compared with placebo, the proportion of IXEQ2W and IXEQ4W patients who achieved ASAS 40% response was significantly greater at week 16 (30.6 and 25.4%, respectively, vs 12.5%), with statistically significant differences seen as early as week 1 of treatment.